Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals (Nasdaq: XENE) will present at four investor conferences in Q2 2026: Bloom Burton (Apr 22), Bank of America (May 14), RBC (May 19) and Jeffries (Jun 4).
Webcast details and replay availability will be posted on the company Investors section; dates and times are subject to change.
Xenon (Nasdaq: XENE) will present five abstracts at the AAN Annual Meeting April 18-22, 2026, including a Late-breaking Science oral and poster of topline Phase 3 X-TOLE2 results for azetukalner in focal onset seizures and a ≥48-month interim analysis from the X-TOLE open-label extension.
Additional presentations cover real-world titration burden, comorbidity impacts, and preclinical NaV1.1 Dravet data; Xenon will staff Booth #2330 in the exhibit hall.
Xenon Pharmaceuticals (Nasdaq: XENE) closed an upsized underwritten public offering on March 12, 2026, raising approximately $747.5 million in gross proceeds.
The company sold 12,236,843 common shares (including 1,710,526 shares from full exercise of the underwriters' option) and issued pre-funded warrants to purchase up to 877,194 common shares at $56.9999 each; each pre-funded warrant has an exercise price of $0.0001.
Xenon Pharmaceuticals (Nasdaq: XENE) priced an upsized underwritten public offering totaling 10,526,317 common shares and pre-funded warrants for 877,194 shares at $57.00 per common share (pre-funded warrants $56.9999), raising approximately $650.0 million in gross proceeds.
The offering includes a 30-day underwriter option to buy up to 1,710,526 additional common shares and is expected to close on or about March 12, 2026. The securities were registered on a shelf registration filed August 9, 2024. No sales are being made in Canada.
Xenon Pharmaceuticals (Nasdaq: XENE) announced a proposed underwritten public offering of $500.0 million of common shares, with underwriters having a 30-day option to purchase up to an additional $75.0 million. All shares are being offered by Xenon and the offering is subject to market and other conditions.
Joint book-running managers include J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair; an effective shelf registration was filed on August 9, 2024. The offering will be made only by prospectus and prospectus supplement.
Xenon (Nasdaq: XENE) reported positive topline Phase 3 X-TOLE2 results for azetukalner in focal onset seizures (FOS) on March 9, 2026. The trial met its primary endpoint with a -53.2% median percent change (MPC) in monthly FOS frequency for 25 mg versus -10.4% for placebo (placebo-adjusted -42.7%, p=6e-12).
Key secondary RR50 was 54.8% (25 mg) versus 20.8% placebo. Safety was consistent with prior studies. Xenon plans to file an NDA in Q3 2026 and will present X-TOLE2 as a Late Breaking Science oral at AAN on April 19, 2026.
Xenon Pharmaceuticals (Nasdaq: XENE) will announce topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures on Monday, March 9, 2026. A live webcast and replay will be available via the company's Investors website; conference call details are provided.
Conference call: 8:00 am ET (5:00 am PT) on March 9, 2026; dial-in and webcast registration information available.
Xenon Pharmaceuticals (Nasdaq: XENE) reported Q4 and full-year 2025 results and a business update highlighting imminent clinical and cash milestones. X-TOLE2 Phase 3 topline data in focal onset seizures are expected in the first half of March 2026, with an anticipated NDA submission in H2 2026. Pro forma cash of $716.0M (including Q1 2026 ATM proceeds) supports operations into the second half of 2027. Multiple Phase 3 azetukalner studies continue to enroll; X-NOVA2 MDD topline data expected H1 2027. Early-stage Phase 1 data for XEN1701 and XEN1120 expected in 2026.
Xenon Pharmaceuticals (Nasdaq: XENE) announced inducement equity grants to ten new non-officer employees totaling 42,300 share options, approved by the Compensation Committee with an effective date of January 15, 2026 under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $40.74 per share (equal to the closing price on the grant date), vest over four years with 25% vesting after one year and the remainder vesting monthly (1/36th) thereafter, and each option has a 10-year term and is subject to the company’s 2025 Inducement Equity Incentive Plan and option agreements.
Xenon Pharmaceuticals (Nasdaq: XENE) outlined near-term clinical and regulatory milestones at the 2026 J.P. Morgan Healthcare Conference. Key timelines include X-TOLE2 topline data in March 2026 for azetukalner in focal onset seizures (380 patients randomized) and an anticipated NDA submission in H2 2026. Five additional placebo-controlled Phase 3 azetukalner studies remain active across epilepsy and neuropsychiatry, with X-NOVA2 topline data expected H1 2027 for major depressive disorder. Phase 1 SAD/MAD data for pain candidates XEN1701 (NaV1.7) and XEN1120 (KV7) are expected in 2026 to support Phase 2 proof-of-concept studies. The company also reported long-term OLE results showing sustained seizure reductions and detailed plans to support regulatory filings in multiple regions.